Drugs / Ledipasvir/Sofosbuvir
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT03903185 Comparator | Mar 2019 → Jul 2023 | chronic hepatitis C virus infection, hematopoietic and lymphoid cell neoplasm | Ain Shams University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ledipasvir/Sofosbuvir | “Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancies: A Pharmacokinetic Study.” PMID 37925363 ↗ Nov 2023 |
| Route | Oral | “45 mg of ledipasvir and 200 mg of sofosbuvir orally, once daily with food” NCT03903185 ↗ |